Sera in the news

Sera Prognostics reported Q3 2025 results showing early commercial progress, a net loss, strong cash reserves, and ongoing payer discussions with a Medicaid pilot in Nevada.

Sera Prognostics' CIO sold shares amid a recent stock drop; the company beat EPS forecasts but missed revenue, appointed a new CMO to boost clinical efforts.

Sera AI secured €1.5 million seed funding to expand its AI-driven B2B sales prospecting platform internationally.

Sera AI secured €1.5M seed funding to expand its AI-driven lead qualification platform internationally and enhance sales efficiency.

Estonian startup Sera AI raised €1.5M to expand its AI-powered platform that automates lead qualification and sales prospecting internationally.

Sera Prognostics named Dr. Tiffany Inglis as Chief Medical Officer to lead clinical efforts around the PreTRM® Test amid key study publications and Medicaid pilots.

Sera Prognostics named Dr. Tiffany Inglis as Chief Medical Officer to advance its PreTRM Test for early prediction of preterm birth and improve maternal and neonatal health outcomes.

Sera AI raised €1.5 million seed funding to expand its AI-powered sales agent that automates and personalizes B2B lead qualification and outreach internationally.

Sera Prognostics' CEO sold shares amid weak financials and a cautious stock outlook despite strategic focus on the PreTRM® test.

Sera Prognostics' CEO sold shares amid volatile stock trading and mixed Q2 2025 results with earnings beating but revenue missing estimates.

Sera Prognostics CFO sold shares to cover taxes amid volatile stock trading and mixed Q2 2025 financial results with earnings beat but weak revenue.

Kenya introduced SERA.ai, an AI tool using large language models to speed up and improve health policy formulation with evidence-based insights.

SERA's CEO and other top executives have been selling shares consistently over the past six months, with mixed institutional investor activity.

Sera Prognostics is advancing commercialization of its PreTRM test to predict and reduce preterm births, demonstrating clinical and economic benefits while targeting Medicaid and commercial plans in select states.

Sera Prognostics advances maternal health diagnostics with its PreTRM test, reducing NICU stays and costs while expanding in the U.S. and Europe backed by strong clinical and financial strategies.

Sera Prognostics exceeded EPS forecasts but missed revenue targets in Q2 2025, focusing on US Medicaid pilots and European market entry with strong cash reserves supporting growth plans.

Xurrent introduced Sera AI, an embedded AI tool that automates and enhances IT service management tasks to boost efficiency and reduce manual work.

Sera Prognostics faces financial challenges with declining revenue and losses, while expanding commercial efforts and preparing for European market entry.

Sera Prognostics is advancing strategic initiatives like data publication, team expansion, and European market entry while facing declining revenue and ongoing losses.

Sera Prognostics beat Q2 EPS estimates but missed revenue expectations, with mixed stock performance over the past year.